ABT-263 (Navitoclax) is a second generation, orally bioavailable small molecule Bcl-2 family protein inhibitor that has entered clinical trials with promising efficacy on CLL [43–46]. The gene discussed is BCL2; the disease is B-cell chronic lymphocytic leukemia.